Please login to the form below

Not currently logged in
Email:
Password:

US CROs to report payments to physicians

New rules to US ‘Sunshine Act’ also apply to CMOs

US contract research organisations (CROs) and contract manufacturing organisation (CMOs) must now declare any payments made to physicians, under new federal regulations impacting the pharmaceutical industry.

The Transparency Report and Reporting of Physician Ownership or Investment Interests, commonly known as the 'Sunshine Act', will require manufacturers of drugs, devices, biological or medical supplies to report payments made to physicians on an annual basis.

The new rules fall under the Patient Protection and Affordable Care Act (ACA) section of the act and apply to companies functioning within US health programmes Medicare, Medicaid or CHIP.

The ruling, released last week, also applies to both CMOs and CROs and will cover "payments and transfers of value", including consulting fees, honoraria, gifts, travel and entertainment.

From August 2013 companies will need to begin collecting data on payments made to physicians, which will then be submitted to the Department of Health and Human Services' (HHS) Centers for Medicare and Medicaid Services (CMS), by the end of March 2014.

"The intent of this law is to bring potential conflicts of interest to light with the goal of driving down healthcare costs," explained Scott Liebman, principal at Porzio, Bromberg & Newman, speaking to Forbes.

14th February 2013

From: Research, Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics